Having trouble accessing articles? Reset your cache.

Abiraterone acetate: Interim Phase III data

Johnson & Johnson unblinded the Phase III COU-AA-301 trial at the recommendation of an independent DMC after a pre-specified interim analysis showed that abiraterone plus prednisone

Read the full 268 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE